Company

Stoke Therapeutics, Inc.

Stoke Therapeutics, Inc. develops RNA-based therapies that increase gene expression for genetic disorders such as Dravet syndrome.

About

Founded in 2014 and headquartered in Bedford, US, Stoke Therapeutics uses its TANGO platform to raise protein output from partially dysfunctional genes. Its lead candidate, zorevunersen (STK-001), is under clinical evaluation for Dravet syndrome. CEO Edward Kaye leads the company, which raised USD 97.5 mn on November 19, 2020, after a June 2019 IPO that raised USD 142.04 mn. The company reported 2024 revenue of USD 36.56 mn.

2Funding rounds

8Investors

Sign in to see more

Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.

Sign in